TY - JOUR
T1 - Incidence of new stroke or new myocardial infarction or death at 39-month follow up in patients with diabetes mellitus, hypertension, or both treated with and without angiotensin-converting enzyme inhibitors or angiotensin receptor blockers
AU - Ravipati, Gautham
AU - Aronow, Wilbert S.
AU - Ahn, Chul
AU - Alappat, Rose M.
AU - McClung, John A.
AU - Weiss, Melvin B.
PY - 2009/1
Y1 - 2009/1
N2 - We investigated in 306 patients, mean age 57 ± 10 years, with diabetes mellitus (202 patients) or hypertension (179 patients), whether treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ARBs) reduced the incidence of new stroke or new myocardial infarction (MI) or death. At 39-month follow up, new stroke or new MI or death developed in 49 of 228 patients (21%) treated with ACE inhibitors or ARBs and in 33 of 78 patients (42%) treated without angiotensin-converting enzyme inhibitors or ARBs (P = 0.0001). Stepwise Cox regression analysis showed that significant independent predictors of the time to development of new stroke or new MI or death were 1) use of angiotensin-converting enzyme inhibitors or ARBs (risk ratio, 0.21), 2) diabetes (risk ratio, 4.01), 3) left ventricular hypertrophy (risk ratio, 6.71), 4) prior stroke (risk ratio,4.00), and 5) prior MI (risk ratio, 3.69).
AB - We investigated in 306 patients, mean age 57 ± 10 years, with diabetes mellitus (202 patients) or hypertension (179 patients), whether treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ARBs) reduced the incidence of new stroke or new myocardial infarction (MI) or death. At 39-month follow up, new stroke or new MI or death developed in 49 of 228 patients (21%) treated with ACE inhibitors or ARBs and in 33 of 78 patients (42%) treated without angiotensin-converting enzyme inhibitors or ARBs (P = 0.0001). Stepwise Cox regression analysis showed that significant independent predictors of the time to development of new stroke or new MI or death were 1) use of angiotensin-converting enzyme inhibitors or ARBs (risk ratio, 0.21), 2) diabetes (risk ratio, 4.01), 3) left ventricular hypertrophy (risk ratio, 6.71), 4) prior stroke (risk ratio,4.00), and 5) prior MI (risk ratio, 3.69).
KW - Angiotensin receptor blocker
KW - Angiotensin-converting enzyme inhibitor
KW - Diabetes mellitus
KW - Hypertension
KW - Left ventricular hypertrophy
KW - Myocardial infarction
KW - Stroke
UR - http://www.scopus.com/inward/record.url?scp=60249097777&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=60249097777&partnerID=8YFLogxK
U2 - 10.1097/MJT.0b013e31804d1b53
DO - 10.1097/MJT.0b013e31804d1b53
M3 - Article
C2 - 19114876
AN - SCOPUS:60249097777
SN - 1075-2765
VL - 16
SP - 2
EP - 4
JO - American Journal of Therapeutics
JF - American Journal of Therapeutics
IS - 1
ER -